Revvity reports that its Signals Software business is launching Signals for Startups, a new program designed to help emerging biotech companies adopt scalable informatics capabilities earlier in their growth journey.
Built for early-stage biotechs, the program combines access to Signals software with guided onboarding and best-practice configurations for smaller biotechs to help accelerate innovation, improve scientific productivity and shorten time-to-value, according to a company spokesperson.
Startup biotechs are often under pressure to move quickly with limited IT, informatics, and operational resources while managing increasingly complex discovery data. Signals for Startups addresses this challenge with a purpose-built, scalable Signals environment that helps teams focus on science while establishing a strong digital foundation from day one, explains Kevin Willoe, president of Revvity Signals Software, adding that out-of-the-box configurations for large and small molecules enable companies to accelerate adoption, standardize data, and enhance collaboration on a proven, scalable informatics infrastructure.
“Signals for Startups addresses a critical need for emerging biotech companies that want to move fast without creating data and workflow challenges that limit their ability to scale,” he continues. “By combining startup-friendly access with guided onboarding and scalable Signals workflows, we are helping early-stage teams build the digital foundation they need to advance discovery, support investor readiness and grow with confidence.”
Signals for Startups is expected to be available in the U.S., Europe, the Middle East, and Africa later this month.